Please assess the completion status of the following clinical trial:

Trial Title: Stereotactic Radiation Therapy With or Without Whole-Brain Radiation Therapy in Treating Patients With Brain Metastases

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
DISEASE CHARACTERISTICS:~* Diagnosis of cerebral metastases meeting the following criteria:~  * One to three presumed brain metastases~ * Metastases must be from a histologically confirmed extracerebral site (e.g., lung, breast, prostate)~    * Histologic confirmation may have been from the primary tumor site, from another metastatic site (e.g., osseous metastasis, adrenal metastasis), or from the metastatic brain lesion(s)~ * Each lesion must measure less than 3.0 cm by contrast MRI of the brain performed within the past 21 days~ * Lesions must not be within 5 mm of the optic chiasm or within the brainstem~* Eligibility for treatment with gamma knife or linear accelerator-based radiosurgery confirmed by a radiation oncologist~* No primary germ cell tumor, small cell carcinoma, or lymphoma~* No leptomeningeal metastases~* Hormone receptor status not specified~PATIENT CHARACTERISTICS:~* Male or female~* Menopausal status not specified~* ECOG performance status 0-2~* Not pregnant~* Negative pregnancy test~* Fertile patients must use effective contraception~  * Male patients must continue to use contraception for 3 months after the completion of radiotherapy~* No pacemaker or other MRI-incompatible metal in the body~* No known allergy to gadolinium~PRIOR CONCURRENT THERAPY:~* More than 7 days since prior and no concurrent chemotherapy~* No prior cranial radiotherapy~* No prior resection of cerebral metastases~* Concurrent hormonal agents, steroids, and/or anticonvulsants allowed

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Arm I (Type: ACTIVE_COMPARATOR): Patients undergo stereotactic radiosurgery (SRS)
- Arm II (Type: EXPERIMENTAL): Patients undergo SRS as in arm I. Within 14 days, patients then undergo whole-brain radiotherapy 5 days a week for 2.5 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).